INTELLIGENT OFFLOADING INSOLE DEVICE
    31.
    发明申请

    公开(公告)号:WO2018093838A1

    公开(公告)日:2018-05-24

    申请号:PCT/US2017/061711

    申请日:2017-11-15

    Abstract: A plantar surface pressure offloading system includes an insole capable of coupling with a shoe and interfacing with a foot. A number of compressible bladders and pressure sensors are coupled to the insole. Each bladder has an adjustable compressibility, and each pressure sensor is configured to measure a pressure exerted on a respective portion of the foot. A controller of the system can perform, for each compressible bladder, a compressibility adjustment process including (i) receiving, from a respective pressure sensor associated with a respective bladder, a signal indicative of a pressure exerted on a respective portion of the foot, (ii) determining, based on the signal, that the pressure exerted on the respective portion of the foot exceeds a threshold pressure, and (iii) responsive to the determination, adjusting the compressibility of the respective bladder, thereby offloading pressure from the respective portion of the foot to a different portion of the foot.

    ALTERNATIVELY SPLICED PRE-MRNA TRANSCRIPTS AS BIOMARKERS IN IDIOPATHIC NEURODEGENERATIVE DISEASES
    34.
    发明申请
    ALTERNATIVELY SPLICED PRE-MRNA TRANSCRIPTS AS BIOMARKERS IN IDIOPATHIC NEURODEGENERATIVE DISEASES 审中-公开
    作为生物标志物在异常神经病变疾病中的替代的前期MRNA转录物

    公开(公告)号:WO2008127317A2

    公开(公告)日:2008-10-23

    申请号:PCT/US2007024543

    申请日:2007-11-29

    CPC classification number: C12Q1/6883 C12Q2600/158

    Abstract: The present invention discloses a method to discover biomarkers indicative of an idiopathic neurodegenerative disease in a mammalian subject and biomarkers indicative of an idiopathic neurodegenerative disease in the mammalian subject. The biomarker comprises a splice variant mRNA of a precursor-messenger RNA (pre-mRNA) transcript of a gene in the mammalian subject wherein (a) the ratio of the amount of the splice variant mRNA to the amount of another splice variant mRNA of the same precursor-messenger RNA (pre-mRNA) transcript of the same gene is different in the mammalian subject having the neurodegenerative disease as compared to that of a control without the disease; or (b) the ratio of the amount of the splice variant mRNA to the amount of total 18S RNA is different in the mammalian subject having the neurodegenerative disease as compared to that of a control without the disease. The biomarkers can be used to diagnose neurodegenerative diseases in the subject.

    Abstract translation: 本发明公开了一种在哺乳动物受试者中发现指示特发性神经变性疾病的生物标志物的方法,以及哺乳动物受试者中指示特发性神经变性疾病的生物标志物。 生物标志物包含哺乳动物受试者中基因的前体 - 信使RNA(前mRNA)转录物的剪接变体mRNA,其中(a)剪接变体mRNA的量与所述剪接变体mRNA的另一个剪接变体mRNA的量的比例 与没有疾病的对照相比,在具有神经变性疾病的哺乳动物受试者中相同基因的相同前体信使RNA(前mRNA)转录物不同; 或(b)与没有疾病的对照相比,在具有神经变性疾病的哺乳动物受试者中,剪接变体mRNA的量与总18S RNA的量的比例是不同的。 生物标志物可用于诊断受试者的神经变性疾病。

    ALTERNATIVELY SPLICED PRE-MRNA TRANSCRIPTS IN NEURODEGENERATIVE DISEASE
    35.
    发明申请
    ALTERNATIVELY SPLICED PRE-MRNA TRANSCRIPTS IN NEURODEGENERATIVE DISEASE 审中-公开
    神经病变疾病中的替代前期预后转录

    公开(公告)号:WO2006026602A2

    公开(公告)日:2006-03-09

    申请号:PCT/US2005/030795

    申请日:2005-08-30

    CPC classification number: C12Q1/6883 C12Q2600/158

    Abstract: The present invention provides a method of diagnosing a neurodegenerative disease in a mammalian subject, preferably a human subject. The method comprises obtaining RNA from the mammalian subject, and assaying the RNA for an increase in the amount of ΔfosB mRNA or in ratio of the amount of ΔFosB mRNA to the amount of FosB mRNA as compared to that of a control. An increase in the amount of ΔFosB mRNA or the ratio of the amount of ΔFosB mRNA to the amount of FosB mRNA as compared to that of the control is indicative of the presence of the neurodegenerative disease.

    Abstract translation: 本发明提供了诊断哺乳动物受试者,优选人受试者的神经变性疾病的方法。 该方法包括从哺乳动物受试者获得RNA,并且与对照相比,测定RNA以增加αfosBmRNA的量,或以FosB mRNA的量与FosB mRNA的量的比例。 FosB mRNA的量的增加或与对照组相比,FosB mRNA与FosB mRNA的量的比例的增加表明存在神经变性疾病。

    COMPOSITIONS AND METHODS TO MODULATE IMMUNE AND INFLAMMATORY RESPONSES
    36.
    发明申请
    COMPOSITIONS AND METHODS TO MODULATE IMMUNE AND INFLAMMATORY RESPONSES 审中-公开
    组合物和调节免疫和炎症反应的方法

    公开(公告)号:WO2004071441A2

    公开(公告)日:2004-08-26

    申请号:PCT/US2004/003969

    申请日:2004-02-10

    Inventor: BEAMAN, Kenneth

    IPC: A61K

    CPC classification number: C07K16/40 A61K2039/505

    Abstract: The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF).

    Abstract translation: 本发明涉及通过调节再生和耐受因子(RTF)来调节受试者的炎症和免疫反应的组合物和方法,其包括免疫激活和抑制炎性反应。

    COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM
    40.
    发明申请
    COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM 审中-公开
    用于反转和抑制蛋白质聚集的化合物及其制备和使用它们的方法

    公开(公告)号:WO2010037135A2

    公开(公告)日:2010-04-01

    申请号:PCT/US2009/058883

    申请日:2009-09-29

    CPC classification number: C07K14/4711 A61K38/00 C07K19/00

    Abstract: The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation - including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, fronto-temporal dementia (FTD), Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).

    Abstract translation: 本发明提供了用于增加蛋白质聚集体清除率的组合物,以及包含它们的药物组合物,以及用于制备和使用它们的方法,包括用于加速CNS中的蛋白质聚集体清除的方法,例如用于治疗以蛋白质聚集为特征的疾病 - 包括 一些退行性神经系统疾病如帕金森病。 在一个方面,本发明的组合物特异性靶向突触核蛋白,β-淀粉样蛋白和/或tau蛋白聚集体,并且本发明的方法可用于特异性地预防,逆转,减缓或抑制突触核蛋白,β-淀粉样蛋白和/或tau 蛋白质聚集。 在替代实施方案中,本发明的组合物和方法用于治疗,预防,逆转(部分或完全)或改善(包括减缓进展)与蛋白质聚集相关或由其引起的退行性神经疾病,例如突触核蛋白,β - 淀粉样蛋白和/或tau蛋白聚集。 一方面,本发明的组合物和方法用于治疗,预防或改善(包括减缓帕金森氏病,颞叶性痴呆(FTD),阿尔茨海默病(AD),路易体病(LBD)和多发性硬化症 系统萎缩(MSA)。

Patent Agency Ranking